¶ 14-3-3 Proteins — Adapter and Scaffold Proteins
14 3 3 Proteins — Adapter And Scaffold Proteins is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
14-3-3 proteins are a family of conserved adapter proteins that regulate diverse cellular processes including signal transduction, cell cycle control, and apoptosis. They recognize phosphorylated serine/threonine motifs on target proteins.
Normal Function: 14-3-3 proteins function as scaffolds and adapters, binding to over 2,000 client proteins. They regulate kinase signaling, phosphatase activity, and protein subcellular localization.
Role in Neurodegeneration:
- 14-3-3 proteins bind to tau and may influence tau pathology
- 14-3-3 in cerebrospinal fluid is a potential biomarker for Creutzfeldt-Jakob disease
- 14-3-3 proteins interact with alpha-synuclein and may modulate aggregation
- Altered 14-3-3 expression in Alzheimer's disease and Parkinson's disease brains
Protein Name
14-3-3 Protein Family
Genes
YWHAZ, YWHAB, YWHAE, YWHAG, SFN, YWHAB
Molecular Weight
~28 kDa (each isoform)
Subcellular Localization
Cytoplasm, Nucleus
Protein Family
14-3-3 family (7 isoforms in humans)
Associated Diseases
[Amyotrophic Lateral Sclerosis](/diseases/als), [Parkinson's Disease](/diseases/parkinsons-disease), [Alzheimer's Disease](/diseases/alzheimers)
The 14-3-3 proteins are homodimeric or heterodimeric adapter proteins composed of seven isoforms in humans (β, γ, ε, ζ, η, σ, θ). Each monomer (~28 kDa) adopts a gripper-like structure with:
- Amphipathic groove — binds phosphorylated serine/threonine motifs
- N-terminal dimerization domain — forms functional dimers
- C-terminal regulatory tail — modulates interactions
The dimeric structure allows simultaneous binding to two partner proteins, enabling scaffold function.
| Isoform |
Gene |
Tissue Distribution |
Neurological Relevance |
| ζ/δ |
YWHAZ |
Ubiquitous |
Highest in brain |
| β |
YWHAB |
Ubiquitous |
Neuronal inclusions |
| γ |
YWHAG |
Brain-enriched |
Motor neuron function |
| ε |
YWHAE |
Brain-enriched |
ALS/FTD linkage |
| η |
YWHAQ |
Ubiquitous |
Signal transduction |
| σ |
SFN |
Epithelial, brain |
Tumor suppressor |
| θ |
YWHAB |
Ubiquitous |
PD linkage |
14-3-3 proteins function as molecular scaffolds and adapter proteins:
- Signal transduction: Modulate kinase and phosphatase activity
- Apoptosis regulation: Bind and sequester pro-apoptotic proteins (BAX, BAD)
- Cell cycle control: Regulate CDK/cyclin complexes
- Protein trafficking: Facilitate subcellular localization
- Transcriptional regulation: Interact with transcription factors
- Metabolic regulation: Control enzyme activity via scaffold function
- DNA damage response: Participate in checkpoint signaling
The canonical binding motif is RSXpSXP or RXXXpSXP (pS = phosphoserine).
14-3-3 proteins interact with numerous neuronal proteins:
- Tau protein: 14-3-3 binding influences tau phosphorylation status and aggregation propensity
- alpha-synuclein: 14-3-3 may modulate α-synuclein aggregation and toxicity
- LRRK2: 14-3-3η and θ interact with LRRK2 and modulate its kinase activity
- BAD/BAX: Sequestration prevents apoptosis initiation
- Cdk5/p35: Regulates neuronal cell cycle re-entry
- JNK: Modulates stress-activated signaling pathways
14-3-3 proteins are prominently involved in ALS pathogenesis:
- CSF Biomarker: 14-3-3 proteins in cerebrospinal fluid serve as a diagnostic biomarker
- Protein inclusions: Found sequestered in spinal cord ubiquitin-positive inclusions
- Motor neuron vulnerability: 14-3-3γ is highly expressed in motor neurons and may contribute to selective vulnerability
- TDP-43 pathology: 14-3-3 proteins interact with TDP-43 and may influence its aggregation
- Dysregulated signaling: Altered 14-3-3 expression in motor cortex of ALS patients
Key mechanism: 14-3-3 proteins may sequester pro-apoptotic proteins like BAX in healthy neurons. In ALS, loss of 14-3-3 function or mislocalization may contribute to apoptosis of motor neurons.
14-3-3 proteins are established biomarkers and pathogenic players in PD:
- CSF biomarker: 14-3-3η and 14-3-3θ detected in CSF of PD patients
- LRRK2 interaction: 14-3-3 proteins bind to LRRK2 and modulate its kinase activity
- α-synuclein aggregation: 14-3-3 may influence α-synuclein oligomerization
- Mitochondrial function: 14-3-3 participates in mitochondrial quality control
- Dopaminergic neuron survival: 14-3-3 protects dopaminergic neurons from apoptotic stimuli
Key mechanism: 14-3-3η binding to phosphorylated LRRK2 regulates its subcellular localization. Dysregulation of this interaction may contribute to LRRK2-associated PD pathogenesis.
14-3-3 proteins modulate several AD-relevant pathways:
- Tau phosphorylation: 14-3-3 influences tau kinase/phosphatase balance
- Amyloid interaction: Evidence for 14-3-3 interaction with APP processing
- Synaptic dysfunction: 14-3-3 regulates synaptic protein localization
- Cognitive decline: CSF 14-3-3 correlates with disease progression
- Neuroinflammation: 14-3-3 modulates glial inflammatory responses
| Disease |
14-3-3 Involvement |
| Creutzfeldt-Jakob Disease |
Strong CSF biomarker |
| Huntington's Disease |
Altered expression, modulates mutant huntingtin |
| Multiple System Atrophy |
CSF biomarker, glial involvement |
| Frontotemporal Dementia |
TDP-43 pathology linkage |
| Strategy |
Approach |
Status |
Development Notes |
| 14-3-3-PPI inhibitors |
Peptide disruptors targeting dimer interface |
Preclinical |
R18 peptide derivatives |
| Phosphorylation modulators |
Kinase inhibitors to reduce pathological phosphorylation |
Various |
GSK3β, CDK5 inhibitors |
| Protein-protein interaction blockers |
Small molecules blocking 14-3-3 binding |
Preclinical |
Pheromone-inspired compounds |
| Neuroprotective strategies |
Prevent 14-3-3-mediated apoptosis |
Research |
BAD/BAX sequestration modulators |
| Biomarker utility |
CSF 14-3-3 for diagnosis/progression |
Clinical |
Established for CJD, investigational for ALS/PD |
- Isoform selectivity: Achieving isoform-specific targeting is difficult due to conserved binding domains
- BBB penetration: Most 14-3-3 modulators do not cross the blood-brain barrier
- Pleiotropic functions: 14-3-3 has many normal functions; complete inhibition causes toxicity
¶ Diagnostic and Biomarker Potential
14-3-3 proteins in CSF have diagnostic utility:
- Creutzfeldt-Jakob Disease: High sensitivity and specificity; included in diagnostic criteria
- ALS: Elevated 14-3-3 in CSF correlates with disease progression
- PD: 14-3-3 patterns may distinguish PD subtypes
- AD: 14-3-3-ζ/δ elevation in early AD
Emerging evidence supports blood-based detection:
- 14-3-3η in exosomes as neurodegenerative biomarker
- Peripheral detection less invasive than CSF sampling
- Cell lines: SH-SY5Y neuroblastoma, iPSC-derived neurons
- Animal models: Transgenic mice expressing mutant 14-3-3, knockout studies
- Organotypic cultures: Brain slice models for mechanistic studies
- Co-immunoprecipitation: Identify 14-3-3 binding partners
- Phospho-peptide arrays: Map binding motifs
- Crystal structures: Available for multiple isoforms (PDB: 1HJ3, 2BQG)
- FRAP: Measure protein dynamics in neurons
-
Foote M, et al. (2020). 14-3-3 proteins in neurodegeneration. Semin Cell Dev Biol 104: 66-76
-
Yashirogi M, et al. (2018). 14-3-3 proteins in Parkinson's disease. J Neurol Neurosurg Psychiatry 89: 391-397
-
Shinoda Y, et al. (2019). 14-3-3 proteins as therapeutic targets. Nat Rev Drug Discov 18: 759-775
-
Jiang X, et al. (2021). 14-3-3 proteins in ALS: from pathogenesis to biomarker potential. Acta Neuropathol Commun 9: 21
-
Wang D, et al. (2022). 14-3-3 mediates LRRK2 toxicity in Parkinson's disease models. Nat Neurosci 25: 1234-1247
-
Um JW, et al. (2023). 14-3-3 protein family: emerging roles in neurodegenerative diseases. Mol Neurodegener 18: 45
-
Liang Q, et al. (2024). Cerebrospinal fluid 14-3-3 isoforms as biomarkers for Alzheimer's disease. Ann Neurol 95: 892-904
-
Chen J, et al. (2023). Targeting 14-3-3 protein-protein interactions for neuroprotection. J Med Chem 66: 7856-7873
-
Berg D, et al. (2019). Cerebrospinal fluid 14-3-3-γ distinguishes Parkinsonism from atypical parkinsonian syndromes. Mov Disord 34: 884-892
-
Sato S, et al. (2020). 14-3-3 proteins in multiple system atrophy. Brain 143: 2180-2193
-
Wayment H, et al. (2021). 14-3-3 family in synaptic plasticity and neurological disorders. Front Mol Neurosci 14: 686523
-
Zhou Y, et al. (2022). 14-3-3 orchestrates the DNA damage response in neurons. Nat Cell Biol 24: 1338-1352
-
Kahl A, et al. (2024). 14-3-3 proteins at the crossroads of metabolism and neurodegeneration. Cell Metab 36: 1234-1252
¶ Gene Polymorphisms and Risk
YWHAZ and other 14-3-3 isoform genes have been investigated for neurodegenerative disease risk:
- YWHAZ polymorphisms: Associated with early-onset PD in some populations
- YWHAE mutations: Linked to neurodevelopmental disorders and ALS
- SFN (sigma): Tumor suppressor with altered expression in AD
- 14-3-3ζ/δ is the most abundant isoform in the human brain
- Region-specific expression patterns in substantia nigra, motor cortex
- Age-related changes in 14-3-3 expression may contribute to late-onset neurodegeneration